MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Takeda Pharmaceutical Co Ltd ADR

Închisă

SectorSănătate

15.19 1.47

Rezumat

Modificarea prețului

24h

Curent

Minim

14.97

Maxim

15.34

Indicatori cheie

By Trading Economics

Venit

-68B

24B

Vânzări

-32B

1.1T

P/E

Medie Sector

34.581

63.778

EPS

0.048

Randament dividend

4.39

Marjă de profit

2.079

Angajați

49,281

EBITDA

-4.3B

380B

Dividende

By Dow Jones

Randament dividend

Medie Sector

4.39%

2.39%

Statistici piață

By TradingEconomics

Capitalizare de piață

47B

Deschiderea anterioară

13.72

Închiderea anterioară

15.19

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Takeda Pharmaceutical Co Ltd ADR Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

30 ian. 2025, 11:02 UTC

Câștiguri

Takeda Pharmaceutical Names U.S. Head Julie Kim as Next CEO -- Update

30 ian. 2025, 07:53 UTC

Câștiguri

Takeda Pharmaceutical Raises Earnings Guidance, Names Julie Kim as New CEO

28 ian. 2025, 00:03 UTC

Acțiuni populare

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

31 oct. 2024, 07:27 UTC

Câștiguri

Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance -- Update

31 oct. 2024, 06:44 UTC

Câștiguri

Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance

31 iul. 2024, 07:19 UTC

Câștiguri

Takeda Pharmaceutical's First-Quarter Profit Rose on Higher Revenue -- Update

31 iul. 2024, 06:29 UTC

Câștiguri

Takeda Pharmaceutical Reports Rise in First-Quarter Net Profit on Higher Revenue

17 iun. 2024, 13:34 UTC

Principalele dinamici ale pieței

Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback

13 mai 2024, 11:26 UTC

Principalele dinamici ale pieței

AC Immunity Shares Soar on Exclusive License Deal with Takeda

9 mai 2024, 07:37 UTC

Câștiguri

Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss -- Update

9 mai 2024, 07:08 UTC

Câștiguri

Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss

30 ian. 2025, 07:12 UTC

Câștiguri

Correct: Takeda: U.S. Business Unit President Julie Kim to Become CEO in June 2026, Not June

30 ian. 2025, 07:08 UTC

Câștiguri

Takeda: U.S. Business Unit President Julie Kim to Become CEO in June

30 ian. 2025, 06:42 UTC

Câștiguri

Takeda 3Q Rev Y1.144T Vs. Y1.111T >4502.TO

30 ian. 2025, 06:40 UTC

Câștiguri

Takeda 3Q Net Y23.8B Vs. Net Y105.7B >4502.TO

30 ian. 2025, 06:36 UTC

Câștiguri

Takeda: to Discontinue Soticlestat Development Program

30 ian. 2025, 06:34 UTC

Câștiguri

Takeda: Program May Repurchase Up to 1.8% of Outstanding Shares

30 ian. 2025, 06:32 UTC

Câștiguri

Takeda: To Buy Back Up to Y100B of Own Shares from Feb. 17 to May 31

30 ian. 2025, 06:31 UTC

Câștiguri

Takeda Pharmaceutical Raises Revenue, Net-Profit Views for FY Ending March

30 ian. 2025, 06:30 UTC

Câștiguri

Takeda Pharmaceutical Sees FY Net Y118.00B

30 ian. 2025, 06:30 UTC

Câștiguri

Takeda Pharmaceutical 9-Mos Net Y211.08B Vs Net Y147.09B

30 ian. 2025, 06:30 UTC

Câștiguri

Takeda Pharmaceutical Sees FY Net Y118.00B

30 ian. 2025, 06:30 UTC

Câștiguri

Takeda Pharmaceutical Raises FY Dividend to Y196.00

30 ian. 2025, 06:30 UTC

Câștiguri

Takeda Pharmaceutical 9-Mos EPS Y133.71 Vs EPS Y94.10

30 ian. 2025, 06:30 UTC

Câștiguri

Takeda Pharmaceutical 9-Mos Pretax Pft Y282.38B Vs Pft Y100.31B

30 ian. 2025, 06:30 UTC

Câștiguri

Takeda Pharmaceutical 9-Mos Oper Pft Y417.52B Vs Pft Y224.14B

30 ian. 2025, 06:30 UTC

Câștiguri

Takeda Pharmaceutical 9-Mos Rev Y3.53T Vs Y3.21T

30 ian. 2025, 06:30 UTC

Câștiguri

Takeda Pharmaceutical 9-Mos Net Y211.08B Vs Net Y147.09B

Comparație

Modificare preț

Takeda Pharmaceutical Co Ltd ADR Așteptări

Consens privind evaluarea

By TipRanks

0 ratings

0

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

14.89 / 15.155Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Strong Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.